Causes and mechanisms of nondipping hypertension

Clinical and Experimental Hypertension

Volumn 30, Issue 7, 2008, Pages 585-597

  Kanbay, Mehmet ^a,c   Turgut, Faruk ^a   Erkmen Uyar, Mehtap ^a   Akcay, Ali ^a   Covic, Adrian ^b  

^a FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

^b C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^c C I PARHON University Hospital ^*  (United States)

Author keywords

Aging; Chronic kidney disease; Dipping nondipping blood pressure; Obesity; Sympathetic system

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM; CYCLOSPORIN A; NEUROHORMONE; PARATHYROID HORMONE; PHOSPHATE; STEROID; TACALCITOL; THYROID HORMONE; VITAMIN D DERIVATIVE;

AUTONOMIC NERVOUS SYSTEM; BEDTIME DOSAGE; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE MONITORING; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; CLINICAL TRIAL; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; HIGH SODIUM INTAKE; HORMONAL REGULATION; HUMAN; HYPERTENSION; LIFESTYLE; METABOLIC SYNDROME X; NIGHT; NUTRITION; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROSTATE HYPERTROPHY; REVIEW; SIDE EFFECT; SLEEP APNEA SYNDROME; SMOKING;

AGING; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CHRONOBIOLOGY DISORDERS; CIRCADIAN RHYTHM; DIABETES COMPLICATIONS; FEMALE; HORMONES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC SYNDROME X; NOCTURIA; OBESITY; PROSTATIC HYPERPLASIA; SLEEP APNEA SYNDROMES; SODIUM, DIETARY;

EID: 54049090388     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960802251974     Document Type: Review

References (96)

1. Chobanian AC, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-2572.
2. O'Brien E, Sheridan J, O'Malley K. Dippers and nondippers. Lancet. 1988;2:397.
3. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368-2374.
4. Verdecchia P, Angeli F, Cavallini C. Ambulatory blood pressure for cardiovascular risk stratification. Circulation. 2007;115:2091-2093.
5. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777-1783.
6. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539-546.
7. Covic A, Goldsmith DJ. Ambulatory blood pressure monitoring in nephrology: Focus on BP variability. J Nephrol. 1999;12:220-229.
8. Peixoto AJ, White WB. Ambulatory blood pressure monitoring in chronic renal disease: Technical aspects and clinical relevance. Curr Opin Nephrol Hypertens. 2002;11:507-516.
9. Kohara K, Nishida W, Maguchi M, Hiwada K. Autonomic nervous function in nondipper essential hypertensive subjects. Evaluation by power spectral analysis of heart rate variability. Hypertension. 1995;26:808-814.
10. Ragot S, Herpin D, Siche JP, Ingrand P, Mallion JM. Autonomic nervous system activity in dipper and nondipper essential hypertensive patients. What about sex differences? J Hypertens. 1999;17:1805-1811.
11. Hojo Y, Noma S, Ohki T, Nakajima H, Satoh Y. Autonomic nervous system activity in essential hypertension: A comparison between dippers and nondippers. J Hum Hypertens. 1997;11:665-671.
12. Fletcher AK, Weetman AP. Hypertension and hypothyroidism. J Hum Hypertens. 1998;12:79-82.
13. Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid. 1996;6:505-512.
14. Park KW, Dai HB, Ojamaa K, Lowenstein E, Klein I, Sellke FW. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg. 1997;85:734-738.
15. Kanbay M, Turgut F, Karakurt F, Isik B, Alkan R, Akcay A, Yigitoglu R, Covic A. Relation between serum thyroid hormone and "nondipper" circadian blood pressure variability. Kidney Blood Press Res. 2007;30:416-420.
16. Dernellis J, Panaretou M. Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. Am Heart J. 2002;143:718-724.
17. Ripoli A, Pingitore A, Favilli B, Bottoni A, Turchi S, Osman NF, De Marchi D, Lombardi M, L'Abbate A, Iervasi G. Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study. J Am Coll Cardiol. 2005;45:439-445.
18. Richelsen B, Sorensen NS. Alpha 2- and beta-adrenergic receptor binding and action in gluteal adipocytes from patients with hypothyroidism and hyperthyroidism. Metabolism. 1987;36:1031-1039.
19. Covic A, Mititiuc I, Gusbeth-Tatomir P, Goldsmith DJ. The reproducibility of the circadian BP rhythm in treated hypertensive patients with polycystic kidney disease and mild chronic renal impairment - a prospective ABPM study. J Nephrol. 2002;15:497-506.
20. Letizia C, Ferrari P, Cotesta D, Caliumi C, Cianci R, Cerci S, Petramala L, Celi M, Minisola S, D'Erasmo E, Mazzuoli GF. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J Hum Hypertens. 2005;19:901-906.
21. Kanbay M, Isik B, Akcay A, Ozkara A, Karakurt F, Turgut F, Alkan R, Uz E, Bavbek N, Yigitoglu R, Covic A. Relation between serum calcium, phosphate, parathyroid hormone and "nondipper" circadian blood pressure variability profile in patients with normal renal function. American Journal of Nephrology. 2007;27:516-521.
22. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607-617.
23. Fliser D, Franek E, Fode P, Stefanski A, Schmitt CP, Lyons M, Ritz E. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant. 1997;12:933-938.
24. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC. Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288:E125-E132.
25. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004;89-90:387-392.
26. Imai Y, Abe K, Sasaki S, Minami N, Nihei M, Munakata M, Murakami O, Matsue K, Sekino H, Miura Y, Yoshioka K. Altered circadian blood pressure rhythm in patients with Cushing's syndrome. Hypertension. 1988;12:11-19.
27. Zacharieva S, Orbetzova M, Stoynev A, Shigarminova R, Yaneva M, Kalinov K, Nachev E, Elenkova A. Circadian blood pressure profile in patients with Cushing's syndrome before and after treatment. J Endocrinol Invest. 2004;27:924-930.
28. Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossman E. Impaired nocturnal melatonin secretion in nondipper hypertensive patients. Blood Pressure. 2003;12:19-24.
29. Zeman M, Dulkova K, Bada V, Herichova I. Plasma melatonin concentrations in hypertensive patients with the dipping and nondipping blood pressure profile. Life Sci. 2005;76:1795-1803.
30. Krzyzanowska K, Schnack C, Mittermayer F, Kopp HP, Hofer M, Kann T, Schernthaner G. High prevalence of abnormal circadian blood pressure regulation and impaired glucose tolerance in adults with hypopituitarism. Exp Clin Endocrinol Diabetes. 2005;113:430-434.
31. Pietrobelli DJ, Akopian M, Olivieri AO, Renauld A, Garrido D, Artese R, Feldstein CA. Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values. J Hum Hypertens. 2001;15:601-605.
32. Nishiyama A, Imai Y, Ohkubo T, Tsuji I, Nagai K, Kikuchi N, Kato J, Sekino M, Aihara A, Kikuya M, Satoh H, Hisamichi S. Determinants of circadian blood pressure variation: A community-based study in Ohasama. Tohoku J Exp Med. 1997;183:1-20.
33. Fagard R, Staessen JA, Thijs L. The relationships between left ventricular mass and daytime and night-time blood pressures: A meta-analysis of comparative studies. J Hypertens. 1995;13:823-829.
34. Kamide K, Kawano Y. Age related hemodynamic changes in the elderly. Nippon Rinsho. 2005;63:969-972.
35. Sundlof G, Wallin BG. Human muscle nerve sympathetic activity at rest. Relationship to blood pressure and age. J Physiol. 1978;274:621-637.
36. Floras JS, Hassan MO, Jones JV, Osikowska BA, Sever PS, Sleight P. Consequences of impaired arterial baroreflexes in essential hypertension: Effects on pressor responses, plasma noradrenaline and blood pressure variability. J Hypertens. 1988;6:525-535.
37. Osanai T, Okuguchi T, Kamada T, et al. Salt-induced exacerbation of morning surge in blood pressure in patients with essential hypertension. J Hum Hypertens. 2000;14:57-64.
38. Uzu T, Ishikawa K, Fujii T, et al. Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation. 1997;96:1859-1862.
39. Wilson DK, Sica DA, Miller SB. Effects of potassium on blood pressure in salt-sensitive and salt-resistant adolescents. Hypertension. 1999;34:181-186.
40. Spallone V, Gambardella S, Maiello MR, Barini A, Frontoni S, Menzinger G. Relationship between autonomic neuropahty, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients. Diabetes Care. 1994;17:578-584.
41. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Battle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002;347:797-805.
42. Mulec H, Blohme G, Kullenberg K, Nyberg G, Bjorck S. Latent overhydration and nocturnal hypertension in diabetic nephropathy. Diabetologia. 1995;38:216-220.
43. Banskota NK, Taub R, Zellner K, Olsen P, King G. Characterization of induction of protooncogene c-myc and cellular growth in human vascular smooth muscle cells in insulin and IGF-1. Diabetes. 1989;38:123-129.
44. Tartan Z, Uyarel H, Kasikcioglu H, Alper AT, Ozay B, Bilsel T, Gul M, Ozturk R, Cam N. Metabolic syndrome as a predictor of nondipping hypertension. Tohoku J Exp Med. 2006;210:57-66.
45. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest. 1985;75:809-817.
46. Swislocki AL, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens. 1989;2:419-423.
47. Della Mea P, Lupia M, Bandolin V, Guzzon S, Sonino N, Vettor R, Fallo F. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens. 2005;18:30-35.
48. Foss CH, Vestbo E, Froland A, Gjessing HJ, Mogensen CE, Damsgaard EM. Normal blood pressure and preserved diurnal variation in offspring of type 2 diabetic patients characterized by features of the metabolic syndrome: The Fredericia Study. Diabetes Care. 2000;23:283-289.
49. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, Sala C, Magrini F, Zanchetti A.Is the nocturnal fall in blood pressure reduced in essential hypertensive patients with metabolic syndrome? Blood Press. 2004;13:230-235.
50. Kannel WB, Brand N, Skinner JJ, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension: The Framingham Study. Ann Intern Med. 1967;67:48-59.
51. Chiang BN, Perlman LV, Epstein FH. Overweight and hypertension: A review. Circulation. 1969;39:403-421.
52. Reisin E, Messerli FG, Ventura HO, Frohlich ED. Renal haemodynamic studies in obesity hypertension. J Hypertens. 1987;5:397-400.
53. Krieger DR, Landsberg L. Mechanisms in obesity-related hypertension: Role of insulin and catecholamines. Am J Hypertens. 1988;1:84-90.
54. Landsberg L, Young JB. Fasting, feeding and regulation of the sympathetic nervous system. N Engl J Med. 1978;298:1295-1301.
55. Scherrer U, Randin D, Tappy L, Vollenweider P, Jequier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994;89:2634-2640.
56. Antic V, Van Vliet BN, Montani JP. Loss of nocturnal dipping of blood pressure and heart rate in obesity-induced hypertension in rabbits. Auton Neurosci. 2001;90:152-157.
57. Carroll JF, Dwyer TM, Grady AW, Reinhart GA, Montani JP, Cockrell K, Meydrech EF, Mizelle HL. Hypertension, cardiac hypertrophy, and neurohumoral activity in a new animal model of obesity. Am J Physiol. 1996;271:H373-H378.
58. Antic V, Tempini A, Montani JP. Serial changes in cardiovascular and renal function of rabbits ingesting a high-fat, high-calorie diet. Am J Hypertens. 1999;12:826-829.
59. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87:2246-2252.
60. Afsar B, Sezer S, Elsurer R, Ozdemir FN. Is HOMA index a predictor of nocturnal nondipping in hypertensives with newly diagnosed type 2 diabetes mellitus? Blood Press Monit. 2007;12:133-139.
61. Farmer CK, Goldsmith DJ, Cox J, Dallyn P, Kingswood JC, Sharpstone P. An investigation of the effect of advancing uremia, renal replacement therapy and renal transplantation on blood pressure diurnal variability. Nephrol Dial Transplant. 1997;12:2301-2307.
62. Peixoto AJ, White WB. Ambulatory blood pressure monitoring in chronic renal disease: Technical aspects and clinical relevance. Curr Opin Nephrol Hypertens. 2002;11:507-516.
63. London GM, Guerin AP, Marchais SJ, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int. 1996;50:600-608.
64. Liu M, Takahashi H, Morita Y, Maruyama S, Mizuno M, Yuzawa Y, Watanabe M, Toriyama T, Kawahara H, Matsuo S. Nondipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Nephrol Dial Transplant. 2003;18:563-569.
65. Zoccali C, Benedetto FA, Tripepi G, et al. Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney Int. 1998;53:1078-1084.
66. Zoccali C, Mallamaci F, Tripepi G, et al. Autonomic neuropathy is linked to nocturnal hypoxemia and to concentric hypertrophy and remodeling in dialysis patients. Nephrol Dial Transplant. 2001;16:70-77.
67. Mansoor GA, White WB. Circadian blood pressure variation in hypertensive patients with primary hyperaldosteronism. Hypertension. 1998;31:843-847.
68. Lund-Johansen P, White WB. Central hemodynamics and 24-hour blood pressure in obstructive sleep apnea syndrome: Effects of corrective surgery. Am J Med. 1990;88:678-682.
69. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic 28. Neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96:1897-1904.
70. Ceruti M, Petramala L, Cotesta D, Cerci S, Serra V, Caliumi C, Iorio M, De Toma G, Ciardi A, Vitolo D, Letizia C. Ambulatory blood pressure monitoring in secondary arterial hypertension due to adrenal diseases. J Clin Hypertens (Greenwich). 2006;8:642-648.
71. Penzo M, Palatini P, Rossi GP, Zanin L, Pessina AC. In primary aldosteronism the circadian blood pressure rhythm is similar to that in primary hypertension. Clin Exp Hypertens. 1994;16:659-673.
72. Spieker C, Barenbrock M, Rahn KH, Zidek W. Circadian blood pressure variations in endocrine disorders. Blood Press. 1993;2:35-39.
73. Zelinka T, Strauch B, Pecen L, Widimsky J Jr. Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome. J Hum Hypertens. 2004;18:107-111.
74. Zelinka T, Strauch B, Petrak O, Holaj R, Vrankova A, Weisserova H, Pacak K, Widimsky J Jr. Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. J Hypertens. 2005;23:2033-2039.
75. Young T, Peppard P, Palta M, Hla KM, Finn L, Morgan B, Skatrud J. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med. 1997;157:1746-1752.
76. Malone S, Liu PP, Holloway R, Rutherford R, Xie A, Bradley TD. Obstructive sleep apnoea in patients with dilated cardiomyopathy: Effects of continuous positive airway pressure. Lancet. 1991;338:1480-1484.
77. Koskenvuo M, Kaprio J, Partinen M, Langinvanio H, Sarna S, Heikkila K. Snoring as a risk factor for hypertension and angina pectoris. Lancet. 1985;1:89-95.
78. Hung J, Whitford EG, Parsons RW, Hillman RW. Association of sleep apnoea with myocardial infarction in men. Lancet. 1990;336:261-264.
79. Dyken ME, Somers VK, Yamada T, Ren ZY, Zimmerman MB. Investigating the relationship between stroke and obstructive sleep apnea. Stroke. 1996;27:401-407.
80. Partinen M, Guilleminault C. Daytime sleepiness and vascular morbidity at seven-year followup in obstructive sleep apnea patients. Chest. 1990;97:27-32.
81. Phillips BG, Narkiewicz K, Pesek CA, Haynes WG, Dyken ME, Somers VK. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens. 1999;17:61-66.
82. Schulz R, Schmidt D, Blum A, Lopes-Ribeiro X, Lucke C, Mayer K, et al. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnea: Response to CPAP therapy. Thorax. 2000;55:1046-1051.
83. Narkiewicz K, Montano N, Cogliati C, van de Borne PJ, Dyken ME, Somers VK. Altered cardiovascular variability in obstructive sleep apnea. Circulation. 1998;98:1071-1077.
84. Ziegler MG, Mills PJ, Loredo JS, Ancoli-Israel S, Dimsdale JE. Effect of continuous positive airway pressure and placebo treatment on sympathetic nervous activity in patients with obstructive sleep apnea. Chest. 2001;120:887-893.
85. Dimsdale JE, Loredo JS, Profant J. Effect of continuous positive airway pressure on blood pressure: A placebo trial. Hypertension. 2000;35:144-147.
86. Asplund R. Nocturia in relation to sleep, health, and medical treatment in the elderly. BJU Int. 2005;96:15-21.
87. Bao X, Nelesen RA, Loredo JS, Dimsdale JE, Ziegler MG. Blood pressure variability in obstructive sleep apnea: Role of sympathetic nervous activity and effect of continuous positive airway pressure. Blood Press Monit. 2002;7:301-307.
88. Natsume O. A clinical investigation of nocturnal polyuria in patients with nocturia: A diurnal variation in arginine vasopressin secretion and its relevance to mean blood pressure. J Urol. 2006;176:660-664.
89. Turgut F, Bayrak O, Kanbay M, Ozkara A, Uz E, Bavbek N, Kargili A, Akcay A. Circadian rhythm of blood pressure in patients with benign prostatic hyperplasia Scand J Urol Nephrol. 2008;42:47-52.
90. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol. 2004;172:1390-1393.
91. McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2005;174:1327-1333.
92. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, Mancini M, Trevisan M. Serum uric acid and hypertension: The Olivetti Heart Study. J Hum Hypertens. 1994;8:677-681.
93. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28-33.
94. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39:1227-1233.
95. Morillo MG, Amato MC, Cendon Filha SP. Twenty-four hour blood pressure record for smokers and nonsmokers. Arq Bras Cardiol. 2006;87:504-511.
96. Hermida RC, Ayala DE, Calvo C. Optimal timing for antihypertensive dosing: Focus on valsartan. Ther Clin Risk Manag. 2007 Mar;3 (1):119-131.